About M8 Pharmaceuticals
M8 Pharmaceuticals is a company based in Berwyn (United States) founded in 2007 was acquired by Acino in December 2023. M8 Pharmaceuticals has raised $264.41 million across 9 funding rounds from investors including Teva Pharmaceuticals, TPG and Knight Therapeutics. M8 Pharmaceuticals offers products and services including Innovative Medicines and Partnership Services.
- Headquarter Berwyn, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name M8 Pharmaceuticals, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$264.41 M (USD)
in 9 rounds
-
Latest Funding Round
$25 M (USD), Debt – Conventional
Feb 01, 2019
-
Investors
Teva Pharmaceuticals
& 4 more
-
Employee Count
Employee Count
-
Acquired by
Acino
(Dec 04, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of M8 Pharmaceuticals
M8 Pharmaceuticals offers a comprehensive portfolio of products and services, including Innovative Medicines and Partnership Services.
Innovative medicines are developed and commercialized in therapeutic areas like Central Nervous System and Oncology
Strategic partnerships are formed for licensing and commercialization of medicines in global markets
Funding Insights of M8 Pharmaceuticals
M8 Pharmaceuticals has successfully raised a total of $264.41M across 9 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $25 million completed in February 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Debt – Conventional — $25.0M
-
First Round
First Round
(30 Jan 2008)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2019 | Amount | Debt – Conventional - M8 Pharmaceuticals | Valuation |
investors |
|
| Oct, 2012 | Amount | Series E - M8 Pharmaceuticals | Valuation | Forest Laboratories |
|
| Oct, 2010 | Amount | Series D - M8 Pharmaceuticals | Valuation | Teva Pharmaceuticals |
|
Investors in M8 Pharmaceuticals
M8 Pharmaceuticals has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Teva Pharmaceuticals, TPG and Knight Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Fund of funds focused on pre-seed and seed-stage companies
|
Founded Year | Domain | Location | |
|
Prescription pharmaceuticals are acquired, licensed, and commercialized by the company.
|
Founded Year | Domain | Location | |
|
Pharmaceutical formulations are developed and marketed by Forest Laboratories.
|
Founded Year | Domain | Location |
Investments & Acquisitions by M8 Pharmaceuticals
Financial Statements - M8 Pharmaceuticals
M8 Pharmaceuticals Comparisons
Competitors of M8 Pharmaceuticals
Latest news on M8 Pharmaceuticals
Frequently Asked Questions about M8 Pharmaceuticals
M8 Pharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
M8 Pharmaceuticals is headquartered in Berwyn, United States. It is registered at Berwyn, Illinois, United States.
Joel Barlan is the current CEO of M8 Pharmaceuticals.
M8 Pharmaceuticals is a funded company, having raised a total of $264.41M across 9 funding rounds to date. The company's 1st funding round was a Series D of $60.97M, raised on Jan 30, 2008.
M8 Pharmaceuticals was founded in 2007 and is headquartered in Berwyn, United States. Operations in the pharmaceutical sector involve partnerships with other companies to develop and commercialize original medicines. Access to established treatments is facilitated for patients across Latin America, with a focus on regional distribution and market entry strategies. Leadership is provided by CEO Joel Barlan.
M8 Pharmaceuticals offers Innovative Medicines and Partnership Services.
M8 Pharmaceuticals has 5 investors. Key investors include Teva Pharmaceuticals, TPG, Knight Therapeutics, Forest Laboratories, and Acino.